glp-1 obesity market news today Goldman Sachs raises drug forecast: Oral enters mass market, projected to reach $114 billion by 2030 New Demand in an Old

Although uncommon, identifying these patterns early can guide dose adjustments or therapy changes when necessary

A randomized, placebo-controlled, double-blind, crossover trial was conducted in 42 patients with type 2 diabetes

Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS

These hormones regulate metabolism, energy expenditure, and numerous physiological processes throughout the body

Electrolyte monitoring is not routinely required for all GLP-1 users, but becomes essential when patients experience persistent gastrointestinal symptoms or have additional risk factors such as chronic kidney disease, heart failure, age over 65, or concurrent diuretic use